M. A. Nauck Et Al. , "Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS," CARDIOVASCULAR DIABETOLOGY , vol.18, no.1, 2019
Nauck, M. A. Et Al. 2019. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. CARDIOVASCULAR DIABETOLOGY , vol.18, no.1 .
Nauck, M. A., McGuire, D. K., Pieper, K. S., Lokhnygina, Y., Strandberg, T. E., Riefflin, A., ... DELİBAŞI, T.(2019). Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. CARDIOVASCULAR DIABETOLOGY , vol.18, no.1.
Nauck, Michael Et Al. "Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS," CARDIOVASCULAR DIABETOLOGY , vol.18, no.1, 2019
Nauck, Michael A. Et Al. "Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS." CARDIOVASCULAR DIABETOLOGY , vol.18, no.1, 2019
Nauck, M. A. Et Al. (2019) . "Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS." CARDIOVASCULAR DIABETOLOGY , vol.18, no.1.
@article{article, author={Michael A. Nauck Et Al. }, title={Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS}, journal={CARDIOVASCULAR DIABETOLOGY}, year=2019}